[ad_1] You can’t completely blame Pfizer’s executives, yet Roche’s $7 billion acquisition of a bowel-disease treatment that it owned until last year isn’t a great look. In a deal that…
Tag: Roivant Sciences
Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion
[ad_1] Updated Oct. 23, 2023 6:55 am ET Roche Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences, a company started by Republican presidential candidate…
Vivek Ramaswamy’s Former Company Is Doing Just Fine Without Him
[ad_1] Roivant wouldn’t be where it is without the Republican presidential candidate, but his departure has made the company more palatable to Wall Street. [ad_2] Source link
The Brash Strategy That Made Vivek Ramaswamy a Fortune
[ad_1] Updated Sept. 9, 2023 10:51 am ET Vivek Ramaswamy was a novice biotech entrepreneur in 2016 with no advanced medical training and no record of developing drugs. Copyright ©2023…
Collecting Pharma’s Scraps Can Pay Off for This Biotech
[ad_1] Markets Heard on the Street Roivant has built a unique model that allows it to benefit from big pharma’s need to reduce R&D spending [ad_2] Source link